Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 14 FEBRUARY 2018

Securing Financing For Zealand Pharma's Operations Through US$50 Million Royalty Stream Securitization

Dechert LLP
Explore more from Dechert LLP

Zealand Pharma A/S ("Zealand") (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel ...

GermanyFinance and Banking
Kristopher D. Brown
Kristopher D. Brown
Jonathan Schur
Jonathan Schur
Dr. Karl Von Rumohr
Dr. Karl Von Rumohr
Malcolm S. Dorris
Malcolm S. Dorris
Joshua A.O. Strathman
Joshua A.O. Strathman

The Opportunity

Zealand Pharma A/S ("Zealand") (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and is in Phase III development as a single-injection combination with Lantus®, Sanofi's blockbuster long-acting insulin, together referred to as LixiLan, in both cases under a global license agreement with a German affiliate of Sanofi ("Sanofi").

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

From Rulebook To Market Architecture: MiCAR 1.0, The Emerging MiCAR 2.0, MISP And The EU–UK–US Divide

The Markets in Crypto-Assets Regulation (MiCAR) was designed to bring crypto-assets within a common EU regulatory perimeter, but recent developments reveal a more complex picture. Three decisive developments in October 2026—the Council's position on the Market Integration and Supervision Package, the MiCAR review consultation responses, and ESMA's supervisory action—expose critical gaps in how digital money, tokenised financial instruments, and market infrastructure fit together.
European UnionFinance and Banking
PwC Legal Germany
PwC Legal Germany
Article

MiCAR 2.0: Reading The Further ESMA, ESRB, AMLA And SRB Responses Together

European financial regulators ESMA, ESRB, AMLA, and SRB have published responses to the EU's Markets in Crypto-Assets Regulation review, proposing reforms across classification, market conduct, financial crime controls, and crisis management. The responses raise critical questions about crypto-asset service providers' permissions, client rights, and operational continuity during participant failures. Firms face three immediate priorities: remediating non-compliant stablecoin services by early 2027, testing
GermanyFinance and Banking
PwC Legal Germany
PwC Legal Germany
Article

MISP Moves Into Political Negotiation: What More Than 1,900 Amendments Mean For The EU’s Future Market Architecture

The European Parliament has tabled over 1,900 amendments to the Market Integration and Supervision Package, transforming it from a straightforward proposal into a complex negotiation between competing models for European market supervision and infrastructure. As the Commission's original December 2025 proposal becomes obsolete and multiple parliamentary drafts emerge with conflicting visions, financial firms face critical questions about which supervisory architecture will ultimately govern their licenses
GermanyFinance and Banking
PwC Legal Germany
PwC Legal Germany